Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;21(2):348-352.
doi: 10.1016/j.jcf.2021.08.010. Epub 2021 Sep 1.

Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis

L H Cameron  1 , C A Peloquin  2 , P Hiatt  3 , M Mann  3 , J R Starke  4 , J Faircloth  5 , J C McNeil  4 , A Patel  3 , F Ruiz  3
Affiliations
Free article

Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis

L H Cameron et al. J Cyst Fibros. 2022 Mar.
Free article

Abstract

Few studies have evaluated clofazimine (CLOF) drug monitoring and safety in children. We treated 10 children, 8 with CF, for NTM infection with multiple antimicrobials, including CLOF. All had serial blood CLOF concentrations measured and were followed for adverse events. Despite CLOF dose escalation, most children with CF did not reach a target CLOF concentration. Our data suggest that children with CF may require earlier initiation of CLOF at higher doses than is currently recommended.

Keywords: Clofazimine; Mycobacterium abscessus; Mycobacterium avium intracellularae; NTM; Non-tuberculous mycobacterium infections in children.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest (each author) Lindsay H. Cameron. I have no relevant conflicts of interest to disclose. Chuck A. Peloquin. I have no conflicts of interest to disclose. Michelle Mann. I have no relevant conflicts of interest to disclose. Peter Hiatt. I have no relevant conflicts of interest to disclose. Jeffery R. Starke. I have no conflicts of interest to disclose. Jonathon C. McNeil. I receive funding through AHRQ R01 HS026896. I have received laboratory materials through an investigator initiated research program sponsored by Allergan. I am the site PI on a clinical trial sponsored by Nabriva Therapeutics. These studies are unrelated to the work under consideration. Jenna Faircloth. I have no relevant conflicts of interest to disclose. Ami Patel. I have no conflicts of interest to disclose. Fadel Ruiz. I receive funding from Vertex Pharmaceutical Company as a principle investigator for several CFTR modulator research projects. I receive grant funding from the Cystic Fibrosis Foundation for CF center resources to support a multidisciplinary team.

MeSH terms